Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care.
Hagen B HuttnerStefan T GernerJoji B KuramatsuStuart J ConnollyJan Beyer-WestendorfAndrew M DemchukSaskia MiddeldorpElena ZotovaJulia AlteversFrank AndersohnMary J ChristophPatrick YueLeonhard StrossStefan SchwabPublished in: Stroke (2021)
As compared with usual care, andexanet alfa was associated with a lower rate of HE in atraumatic factor-Xa inhibitor-related ICH, however, without translating into significantly improved clinical outcomes. A comparative trial is needed to confirm the benefit on limiting HE and to explore clinical outcomes across patient subgroups and by time to treatment.